SFRT with tislelizumab and platinum chemotherapy for initially unresectable stage III NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional Phase 2/3 study gives concurrent induction spatially fractionated radiotherapy (SFRT) together with tislelizumab and a platinum-based doublet chemotherapy to try to convert initially unresectable stage III NSCLC to resectable disease. About 30 patients without known EGFR or ALK mutations, aged 18 or older with ECOG 0-1 and T3-4N1-2M0 disease, will be enrolled at a single center. Treatment includes SFRT plus systemic tislelizumab and carboplatin-based chemotherapy (with pemetrexed or paclitaxel per histology), followed by restaging to determine surgical candidacy and close safety monitoring. The study's main outcomes are the surgical resection rate after induction and the adverse reactions experienced with this combined approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient has histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) that is deemed unresectable after discussion in the multidisciplinary team (MDT), which is classified as T3-4N1-2M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC).

Exclusion Criteria:

* Has participated in another clinical study using research products within the past 3 weeks.

Where it's running

• Nanchang City, Jiangxi Province
  Nanchang, Jiangxi, China Recruiting

Study contacts

• Study coordinator: jing cai Jing Cai
• Email: cjdl879@163.com
• Phone: 15270905381

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• RC148 plus platinum chemotherapy versus tislelizumab plus platinum chemotherapy for first-line squamous non-small cell lung cancer

  This study tests whether RC148 with carboplatin and paclitaxel works better than tislelizumab with the same chemotherapy for people with newly diagnosed advanced or metastatic squamous non-small cell lung cancer who have not had prior systemic treatment.

  Recruiting at 78 sites Phase 3 RemeGen Co., Ltd. · Hefei, Anhui and 77 other locations · NCT07416474

• Concurrent chemoradiotherapy with surufatinib and tislelizumab for unresectable stage III non-small cell lung cancer

  This tests whether adding surufatinib and tislelizumab to standard concurrent chemoradiotherapy, followed by continuing both drugs as consolidation, helps people with unresectable stage III non-small cell lung cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07086456

• Neoadjuvant low-dose radiation and SBRT with tislelizumab plus platinum chemotherapy for stage IIA–IIIB NSCLC

  This test tries to see if giving low-dose radiation and SBRT followed by tislelizumab combined with platinum chemotherapy helps people with stage IIA–IIIB non-small cell lung cancer achieve a complete tumor response before surgery.

  Recruiting Phase 2 Sichuan University · Chengdu, China · NCT06877299

• Short-course radiation then tislelizumab plus anlotinib before and after surgery for stage II–IIIA lung cancer

  This study will try short-course radiotherapy followed by the immune drug tislelizumab and the targeted drug anlotinib given before and after surgery for people with stage II–IIIA non-small cell lung cancer.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06379087

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• SYS6010 plus Enlonstobart for recurrent or metastatic nasopharyngeal cancer in patients who have not had prior systemic therapy

  This trial tests whether SYS6010 with Enlonstobart works better than Tislelizumab with gemcitabine and cisplatin for people whose recurrent or metastatic nasopharyngeal cancer has not yet received systemic treatment.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Guangzhou, Guangzhou · NCT07925021

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.